PreprintReviewVersion 1Preserved in Portico This version is not peer-reviewed
Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination
Version 1
: Received: 28 November 2023 / Approved: 29 November 2023 / Online: 29 November 2023 (12:20:42 CET)
How to cite:
Devaux, C.A.; Colson, P.; Raoult, D.; Camoin-Jau, L. Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination. Preprints2023, 2023111883. https://doi.org/10.20944/preprints202311.1883.v1
Devaux, C.A.; Colson, P.; Raoult, D.; Camoin-Jau, L. Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination. Preprints 2023, 2023111883. https://doi.org/10.20944/preprints202311.1883.v1
Devaux, C.A.; Colson, P.; Raoult, D.; Camoin-Jau, L. Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination. Preprints2023, 2023111883. https://doi.org/10.20944/preprints202311.1883.v1
APA Style
Devaux, C.A., Colson, P., Raoult, D., & Camoin-Jau, L. (2023). Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination. Preprints. https://doi.org/10.20944/preprints202311.1883.v1
Chicago/Turabian Style
Devaux, C.A., Didier Raoult and Laurence Camoin-Jau. 2023 "Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination" Preprints. https://doi.org/10.20944/preprints202311.1883.v1
Abstract
Myocarditis has been recognized as a possible rare complication of COVID-19 mRNA vaccination. It concerns between one and five vaccinated people per 100,000 in the general population, with increased incidence in adolescent and young adult men. Most often, cases of myocarditis have been reported in the days following the second dose of vaccine mainly in younger male patients. This rare complication of vaccination usually resolves within days or weeks. However, the pathophysiological events responsible for the increase in frequency of myocarditis after COVID-19 vaccination remain unclear. Several recent reports have highlighted that free spike proteins circulating in the blood of patients at high levels appear to play a major role in myocarditis. Here, we review the most relevant data that partly lift the veil on the molecular mechanisms of the induction of myocarditis following mRNA-based COVID-19 vaccination. We hypothesize that a mechanism of molecular mimicry of the viral spike triggers transient dysregulation of angiotensin-converting enzyme 2, leading to increased soluble angiotensin II binding to the transmembrane receptor angiotensin II type I receptor, similar to what is observed during SARS-CoV-2 infection. We suggest to standardize management of suspected cases of mRNA-based COVID-19 vaccine-induced myocarditis, including angiotensin II and spike antigenemia monitoring.
Keywords
COVID-19 vaccines; mRNA vaccine; SARS-CoV-2 spike; myocarditis; ACE2; renin-angiotensin system
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
